Press Releases Year None20212020201920182017 September 14, 2020 SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma PDF Version August 12, 2020 SpringWorks Therapeutics Reports Second Quarter 2020 Financial Results and Recent Business Highlights PDF Version August 4, 2020 SpringWorks Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference PDF Version July 22, 2020 SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid Tumors PDF Version June 22, 2020 BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial PDF Version June 22, 2020 SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and GlaxoSmithKline’s Belantamab Mafodotin for the Treatment of Relapsed or Refractory Multiple Myeloma PDF Version June 2, 2020 SpringWorks Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference PDF Version May 26, 2020 SpringWorks Therapeutics Appoints Julie Hambleton, M.D. to its Board of Directors PDF Version May 12, 2020 SpringWorks Therapeutics Reports First Quarter 2020 Financial Results and Recent Business Highlights PDF Version March 18, 2020 SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039 PDF Version Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Next page next › Last page last »
September 14, 2020 SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma PDF Version
August 12, 2020 SpringWorks Therapeutics Reports Second Quarter 2020 Financial Results and Recent Business Highlights PDF Version
August 4, 2020 SpringWorks Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference PDF Version
July 22, 2020 SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid Tumors PDF Version
June 22, 2020 BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial PDF Version
June 22, 2020 SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and GlaxoSmithKline’s Belantamab Mafodotin for the Treatment of Relapsed or Refractory Multiple Myeloma PDF Version
June 2, 2020 SpringWorks Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference PDF Version
May 26, 2020 SpringWorks Therapeutics Appoints Julie Hambleton, M.D. to its Board of Directors PDF Version
May 12, 2020 SpringWorks Therapeutics Reports First Quarter 2020 Financial Results and Recent Business Highlights PDF Version
March 18, 2020 SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039 PDF Version
